Human Genome Sciences, Inc.

http://www.hgsi.com/

Human Genome Sciences (HGS) is located in the Washington, DC metro area, and was founded in 1992 with the goal of creating a global biopharmaceutical company to discover, develop, manufacture, and market gene-based drugs to address unmet medical needs. 
They have a product pipeline with seven products in clinical development, including drugs to treat hepatitis C, lupus and other autoimmune diseases, anthrax exposure, and cancer. 

In recent years, they have progressed toward becoming a late stage development and commercialization company, and they have recently (2009) started Phase 3 trials for three of our key development programs.

HGS is developing an innovative new treatment for systemic lupus erythematosus (SLE), which would be the first new treatment for lupus in nearly 40 years. This product, belimumab, is being co-developed and commercialized with Glaxo SmithKline. HGS is also developing a long-acting interferon alpha, Albuferon, for Hepatitis C, along with Novartis. HGS has also been awarded a two-phase contract with US government to supply them with ABthrax, a monoclonal antibody treatment for anthrax, for the Strategic National Stockpile, which we expect to deliver in 2008.

At HGS, people are the key to our success. They share a passion for scientific and business innovation, creating unique opportunities to contribute to the commercialization phase of our products. At HGS, you will have opportunities to learn and grow, interacting with talent of the highest caliber, and you will be supported by a culture committed to employee and leadership development. 

They offer a competitive salary and benefits package. HGS is an Equal Opportunity Employer EOE/AA M/F/D/V.